

Meike Lisette Schipper, MD

EDUCATION

2007-2009	Stanford University Residency, Nuclear Medicine
2006-2007	Molecular Imaging Program at Stanford Research Associate
2003-2006	Molecular Imaging Program at Stanford Post Doctoral Fellow
2001- 2003	Philipps University Marburg, Germany Residency, Nuclear Medicine
2000-2001	Philipps University Marburg, Germany Clinical Year, Internal Medicine
1993-1999	University of Hamburg, Germany MD Degree
12/19/2005	USMLE step II CS
10/27/2005	USMLE step II CK
6/16/2005	USMLE step I
2001	Approbation (German full medical license)
1999	Staatsexamen (German medical exam)
1996	USMLE step I (expired 2003)

MEMBERSHIP

2005	Society of Molecular Imaging (SMI)
2003	Academy of Molecular Imaging (AMI)
2001	German Society of Nuclear Medicine (DGN)
2000	German Endocrine Society (DGE)

HONORS

2003-2004	Research Scholarship, German Research Society. Postdoctoral Scholarship to pursue molecular imaging research at the Molecular Imaging Program at Stanford.
2003	Tyco Healthcare Price Nuclear Medicine: Best Basic Science Paper. German Society of Nuclear Medicine, Essen, Germany, 4/2/03-4/5/03.
2003	One of the ten best European nuclear medicine publications 2003. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
2003	Young Investigator Award 2003 (Co-author). SNM, New Orleans, 21.6.-25.6.03.
2001	Medical Doctorate "magna cum laude". University of Hamburg, Germany.
1992	3 rd in class, Abitur. High school diploma, Theodor Heuss Gymnasium, Goettingen, Germany.
1991	97 th percentile, TMS. German National Medical School Entrance Exam.

MEIKE L. SCHIPPER

RESEARCH

MIPS

- 2006-present *In vivo* biodistribution and tumor targeting of Quantum Dots (With Drs. S. Weiss, UCLA, A. M. Wu, UCLA, and A.E. Ellington, Austin)
- 2005-present *In vivo* toxicity of Single Walled Nanotubes (With Dr. H. Dai)
- 2003-2005 ¹³¹I-FIAU/GCV tumor therapy after HSV1-tk gene transfer (With Dr. M. Goris)
- 2003-2004 Anti-tumor photodynamic therapy using firefly Luciferase as a photon donor
- Philipps University Marburg
- 2000-2003 Radionuclide therapy of neuroendocrine tumors after NIS gene transfer
- 2001-2003 *In vivo* SPECT of NIS gene expression using small animal pinhole collimators.
Dosimetry of internal emitters
Somatostatin/gastrin receptor targeted therapy of neuroendocrine tumors
Calcitonin screening, pentagastrin test and gastrin receptor scintigraphy for diagnosis of medullary thyroid carcinoma
- University of Hamburg
- 1996-1999 Characterization of the two rat APOBEC-1-gene promoters (Medical Doctorate)

GRANTS

- German Cancer Aid (Deutsche Krebshilfe) P.I.: M. L. Schipper, M.D.
“*Therapy and diagnosis of neuroendocrine tumors with radioisotopes following gene transfer of the human sodium iodide symporter (NIS).*” Development of a viral system for in vivo NIS gene transfer for imaging and therapy of neuroendocrine tumors (2004 - 2005).
- P. E. Kempkes Foundation (Private) P.I.: M. L. Schipper, M.D.
“*NIS gene transfer for therapy of neuroendocrine tumors.*” Young Investigator Support; Funds for research materials/supplies (2000 – 2002).
- Grant writing experience
- National Institute of Health/NCI P.I.: S. S. Gambhir, M.D.,
Ph.D.
“*Center of Nanotechnology Excellence focused on Therapy Response (CCNE-TR).*” Development of nanotechnology based applications for improving cancer management (9/05 – 09/10).
- Department of Energy P.I.: M. L. Goris, M.D., Ph.D.
“*Optimizing Radiotherapy of Tumors with Novel Gene Based Therapies for Validation of Radio-Gene Therapy.*” Employing the HSV1-Tk Gene for Combined Suicide Gene Therapy and Targeted Radiotherapy of Tumors (1/05 - 12/07).

TEACHING EXPERIENCE

- 2001-2003 Clinical Instructor Nuclear Medicine, Philipps University Marburg, Germany
- 2000-2001 Clinical Instructor Internal Medicine, Philipps University Marburg, Germany
- 1994 Student Teaching Assistant Anatomy, University of Hamburg, Germany

PUBLICATIONS

1. **Schipper ML**, Nakayama-Ratchford N, Davis CR, Kam NWS, Chu P, Liu Z, Sun X, Dai H, Gambhir SS. *Initial Toxicology Studies of Single Walled Carbon Nanotubes in Mice*. Submitted
2. **Schipper ML**, Cheng Z, Lee SW, Bentolila LA, Iyer G, Rao J, Chen X, Wu AM, Weiss S, Gambhir SS. *MicroPET-Based Biodistribution of Quantum Dots in Living Mice*. J Nucl Med. 2007 (In print).
3. **Schipper ML**, Goris ML, Gambhir SS. *Evaluation of Herpes Simplex Virus 1 Thymidine Kinase Mediated Trapping of ¹³¹I FIAU and Prodrug activation of Ganciclovir as a Synergistic Cancer Radio/Chemotherapy*. Mol Imaging Biol. 2007 May-Jun;9(3):110-6.
4. **Schipper ML**, Riese CGU, Seitz S, Weber A, Béhé M, Schurrat T, Schramm N, Keil B, Alfke H, Behr TM. *Efficacy of ^{99m}Techneium Pertechnetate and ¹³¹Iodide Radioisotope Therapy in Sodium Iodide Symporter (NIS) Expressing Neuroendocrine Tumors In Vivo*. Eur J Nucl Med Mol Imaging. 2007 May;34(5):638-50. Epub 2006 Dec 8.
5. Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, **Schipper ML**, Kalinowski M, Arnold R, Oyen WJG, Behr TM. *Added value of gastrin receptor scintigraphy to somatostatin receptor scintigraphy in neuroendocrine tumours*. Endocrine-Related Cancer. 2006 Dec;13(4):1203-11.
6. Gotthardt M, Behe MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, **Schipper M**, Pollum H, Oyen WJ, Behr TM. *Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma*. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1273-9.
7. **Schipper ML**, Patel MR, Gambhir SS. *Evaluation of Firefly Luciferase Bioluminescence Mediated Photodynamic Toxicity in Cancer Cells*. Mol Imaging Biol. 2006 Jul-Aug;8(4):218-25.
8. Fischer F, Kuhl M, Rominger M, **Schipper ML**, Hadji P, Wagner U, Jackisch C. *Bone Metastases In Vulvar Cancer: A Rare Metastatic Pattern*. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1173-6.
9. Gotthardt M, Lohmann B, Behr TM, Bauhofer A, Franzius C, **Schipper ML**, Wagner M, Hoffken H, Sitter H, Rothmund M, Joseph K, Nies C. *Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic meta-analysis of the literature*. World J Surg. 2004 Jan;28(1):100-7.
10. Gotthardt M, Nowack M, Behe MP, **Schipper ML**, Schlieck A, Hoffken H, Behr TM. *Negative correlation between therapeutic success in radioiodine therapy and TcTUs: are TcTUs-adapted dose concepts the only possible answer?* Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1165-8.
11. **Schipper ML**, Weber A, Behe M, Goke R, Joba W, Schmidt H, Bert T, Simon B, Arnold R, Heufelder AE, Behr TM. *Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells*. Cancer Res. 2003 Mar 15;63(6):1333-8.
12. Gratz S, **Schipper ML**, Dorner J, Hoffken H, Becker W, Kaiser JW, Behe M, Behr TM. *LeukoScan for Imaging Infection in Different Clinical Settings: A Retrospective Evaluation and Extended Review of the Literature*. Clin Nucl Med. 2003 Apr;28(4):267-76.
13. Gotthardt M, **Schipper M**, Franzius C, Behe M, Barth A, Schurrat T, Hoffken H, Gratz S, Joseph K, Behr TM. *Follow-up of perfusion defects in pulmonary perfusion scanning after pulmonary embolism: are we too careless?* Nucl Med Commun. 2002 May;23(5):447-52.
14. Behr TM, Behe M, Kluge G, Gotthardt M, **Schipper ML**, Gratz S, Arnold R, Becker W, Goldenberg DM. *Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis*. Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):277-9.
15. Heufelder AE, Morgenthaler N, **Schipper ML**, Joba W. *Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies*. Thyroid. 2001 Sep;11(9):839-47.
16. Greeve J, Axelos D, Welker S, **Schipper M**, Greten H. *Distinct promoters induce APOBEC-1 expression in rat liver and intestine*. Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1079-92(IF:3.917)

BOOK CHAPTER

1. **Schipper ML**, Gambhir SS. Chapter 15: *Imaging Gene Expression: Concepts and Future Outlook*. Christiaan Schiepers (Ed.). Diagnostic Nuclear Medicine. Springer-Verlag, Berlin, 2005, 2nd edition.

ABSTRACTS (oral presentations only)

1. M. L. Goris, H. J. Zhu, **M. L. Schipper**. *A method to evaluate dosimetry in small animals, using a segmented mouse phantom and convolution filters based on the dose distribution from point sources*. Society of Nuclear Medicine (SNM), Toronto, Canada, 6/18/05-6/22/05.
2. **M. L. Schipper**, M. L. Goris, T. M. Behr, S. S. Gambhir. *I-131-FIAU as a therapeutic agent for radioisotope treatment of HSV1-tk expressing tumors*. German Society of Nuclear Medicine (DGN), Basel, Switzerland, 4/27/05-4/30/05.
3. **M. L. Schipper**, C. G. U. Rebholz, S. Seitz, M. Behe, S. S. Gambhir, T. M. Behr. *I-131 and Tc-99m Pertechnetate significantly reduce growth of sodium-iodide-symporter (NIS) expressing neuroendocrine tumors in vivo*. DGN, Basel, Switzerland, 4/27/05-4/30/05.
4. **M. L. Schipper**, T. Schurrat, H. Alfke, M. Béhé, C. G. U. Rebholz, S. Seitz, L. Maurer, N. Schramm, and T. M. Behr: *SPECT and MRI Fusion of In Vivo Sodium Iodide Symporter (Trans-) Gene Expression in Nude Mice Bearing NIS Transfected Neuroendocrine Tumors*. Academy of Molecular Imaging (AMI), Madrid, Spain, 9/21/03-9/27/03.
5. N. U. Schramm, T. Schurrat, M. Béhé, **M. L. Schipper**, G. Ebel, U. Engeland, T. M. Behr: *Experimental results of a high resolution animal SPECT*. AMI, Madrid, Spain, 9/21/03-9/27/03.
6. M. Béhé, N. Schramm, T. Schurrat, **M. L. Schipper**, H. Höffken, M. Gotthardt, U. Engeland, G. Ebel, T. M. Behr, and H. Alfke: *Animal molecular imaging with a high resolution SPET camera and fused MRI images*. AMI, Madrid, Spain, 9/21/03-9/27/03.
7. **M. L. Schipper**, A. Weber, C. G. U. Rebholz, M. Béhé, T. M. Behr: *Biodistribution of ¹³¹Iodide and ^{99m}Tc Pertechnetate in nude mice bearing NIS expressing neuroendocrine tumors*. European Association of Nuclear Medicine (EANM), Amsterdam, Netherlands, 8/23/03-8/27/03.
8. **M. L. Schipper**, A. Weber, M. Béhé, W. Joba, R. Göke, A. E. Heufelder, T. M. Behr: *In Vitro Therapy of Neuroendocrine Tumor Cells With ¹³¹Iodide After Transfer of The Na/I Symporter Gene*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
9. **M. L. Schipper**, M. Gotthardt, M. Béhé, A. Schlieck, A. Pfestroff, R. Arnold, T. M. Behr: *Therapeutic Efficacy and Toxicity of In-111-DTPA-D-Phe-Octreotide in Patients with Advanced Neuroendocrine Tumors*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
10. M. Gotthardt, **M. L. Schipper**, M. P. Béhé, A. Schlieck, A. Pfestrof, H. Hoeffken, T. Schurrat, B. Herbst, T. M. Behr: *Radioligand therapy using In-111-DTPA-D-Glu1-Minigastrin in patients with metastatic medullary thyroid carcinoma*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
11. M. Gotthardt, M. W. Groß, **M. L. Schipper**, M. Henzel, M. P. Béhé, T. Schurrat, H. Pollum, A. Pfestrof, A. Schmideck, J. Heinis, R. Engenhardt-Cabilic, T. M. Behr: *Uptake of In-111-DTPA-D-Glu1-Minigastrin into malignant brain tumors: Proof of specificity and results of the first 30 patients*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
12. Gotthardt, J. Grass, **M. L. Schipper**, H. Hoeffken, A. Schlieck, T. Schurrat, H. Pollum, M. P. Béhé, T. M. Behr: *Scintigraphy with In-111-DTPA-D-Glu1-Minigastrin and In-111-DTPA-D-Phe1-Octreotide in patients with gastrointestinal neuroendocrine tumors: results of the first 60 patients*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
13. N. U. Schramm, T. Schurrat, M. Béhé, **M. L. Schipper**, G. Ebel, U. Engelandt, T. M. Behr: *Experimental results of a high-resolution animal SPECT*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
14. M. Gotthardt, A. Battmann, D. Beuter, A. Bauhofer, **M. L. Schipper**, M. P. Béhé, K. J. Klose, T. M. Behr: *In-111-DTPA-D-Glu1-Minigastrin is superior to F-18-FDG PET and CT in the diagnosis of metastatic medullary thyroid carcinoma*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.

15. M. Béhé, T. Schurrat, N. Schramm, G. Ebel, H. Alfke, U. Engeland, K. J. Klose, B. Nock, T. Maina, **M. L. Schipper**, T. M. Behr: *Mouse molecular imaging with a high resolution SPECT camera and fused MRI images*. EANM, Amsterdam, Netherlands, 8/23/03-8/27/03.
16. **M. L. Schipper**, A. Weber, M. Béhé, W. Joba, R. Göke, A. E. Heufelder, T. M. Behr: *In vitro Radioiodide Therapy in Neuroendocrine Tumors After Sodium Iodide Symporter (NIS) Gene Transfer*. SNM, New Orleans, 6/23/03-6/25/03.
17. **M. L. Schipper**, M. Gotthardt, M. Béhé, R. Arnold, T. M. Behr: *Therapeutic Efficacy and Toxicity of In-111-DTPA-D-Phe-Octreotide in Patients With Advanced Neuroendocrine Tumors*. SNM, New Orleans, 6/23/03-6/25/03.
19. M. Gotthardt, M. P. Béhé, **M. L. Schipper**, A. Schlieck, H. Hoeffken, T. M. Behr: *In-111-DTPA-D-Glu1-Minigastrin used for therapy of metastatic medullary thyroid carcinoma and other neuroendocrine tumors: results of an ongoing dose-escalation study*. SNM, New Orleans, 6/23/03-6/25/03.
20. N. U. Schramm, M. Béhé, T. Schurrat, **M. L. Schipper**, U. Engeland, G. Ebel, T. M. Behr: *Multi-Pinhole SPECT: Recent results of an animal imaging system*. SNM, New Orleans, 6/23/03-6/25/03.
21. M. Gotthardt, J. Grass, M. P. Béhé, **M. L. Schipper**, A. Schlieck, M. U. Wied, H. Hoeffken, R. Arnold, T. M. Behr: *In-111-DTPA-D-Glu1-Minigastrin in the diagnosis of Gastrointestinal neuroendocrine tumors: a comparison to In-111-Pentetreotide*. SNM, New Orleans, 6/23/03-6/25/03.
22. M. Gotthardt, A. Battmann, D. Beuter, A. Bauhofer, **M. L. Schipper**, M. P. Béhé, W. Lorenz, K. J. Klose, T. M. Behr: *Comparison of In-111-DTPA-D-Glu1-Minigastrin, F-18-FDG PET, and CT scanning for the detection of metastatic medullary thyroid carcinoma*. SNM, New Orleans, 6/23/03-6/25/03.
23. **M. L. Schipper**, M. Gotthardt, M. Béhé, R. Arnold, T. M. Behr: *Therapeutic efficacy and toxicity in advanced neuroendocrine tumour patients*. 16th international IRIST meeting, Capri, Italy, 5/8/03-5/10/03.
24. **M. L. Schipper**, A. Weber, M. Béhé, R. Göke, W. Joba, A. Heufelder, T. M. Behr: *In vitro Radiojodtherapie nach Gentransfer des humanen Natrium-Jodid-Symporters (NIS)*. DGN, Essen, Germany, 4/2/03-4/5/03.
25. **M. L. Schipper**, A. Weber, C. Rebholz, M. Béhé, W. Joba, A. E. Heufelder, T. M. Behr: *Bioverteilung von I-131 und Tc-99m Per technetat in Nacktmäusen mit stabil mit dem Natrium-Jodid-Symporter (NIS) transfizierten neuroendokrinen Tumoren (NIS)*. DGN, Essen, Germany, 4/2/03-4/5/03.
26. **M. L. Schipper**, M. Gotthardt, M. Béhé, A. Schlieck, A. Pfestroff, R. Arnold, T. M. Behr: *Therapeutische Effektivität und Toxizität von In-111-DTPA-D-Phe-Octreotide bei Patienten mit fortgeschritten metastasierten neuroendokrinen Tumoren*. DGN, Essen, Germany, 4/2/03-4/5/03.
27. M. Gotthardt, **M. L. Schipper**, M. Béhé, A. Schlieck, A. Pfestroff, A. Höffken, T. M. Behr: *Results of an ongoing dose-escalation study with In-111-DTPA-D-Glu1-Minigastrin used for therapy of medullary thyroid carcinoma and other neuroendocrine tumors*. DGN, Essen, Germany, 4/2/03-4/5/03.
28. M. Gotthardt, J. Grass, **M. L. Schipper**, H. Höffken, A. Schlieck, M. Béhé, T. M. Behr: *In-111-D-Glu-Minigastrin versus In-111-Pentetreotide in the diagnosis of gastrointestinal neuroendocrine tumors*. DGN, Essen, Germany, 4/2/03-4/5/03.
29. T. M. Behr, M. Gotthardt, **M. L. Schipper**, A. Schlieck, S. Gratz, H. Höffken, M. Béhé: *Cholecystinin (CCK)-B / gastrin receptor binding peptides for diagnosis and therapy of metastatic medullary thyroid cancer (MTC)*. DGN, Essen, Germany, 4/2/03-4/5/03.
30. M. Béhé, T. Maina, B. Nock, M. Gotthardt, A. Schlieck, **M. L. Schipper**, T. Behr: *Erste klinische Erfahrungen mit einem Tc-99m markierten Gastrinanalogen*. DGN, Germany, 4/2/03-4/5/03.
31. T.M. Behr, **M. L. Schipper**, M. Gotthardt, S. Gratz, H. Höffken, M. Béhé, W. Becker: *Factors influencing the therapeutic outcome of 131I therapy of differentiated thyroid cancer (DTC): do we really need stimulated TSH levels?* SNM, Los Angeles, 6/15/02-6/19/02.

32. M. Gotthardt, **M. L. Schipper**, M. Gross, M. Béhé, H. Klauss, R. Engenhardt-Cabilic, H. Bertalanffy, T. M. Behr: *111In-DTPA-D-Glu1-Minigastrin for the determination of viability of malignant brain tumors: initial clinical results*. SNM, Los Angeles, 6/15/02-6/19/02.
33. M. Gotthardt, **M. L. Schipper**, M. Béhé, H. Höffken, S. Gratz, H. Pollum, T. Schurrat, J. Djomotschko, A. Schlieck, K. Goecke, T. M. Behr: *111In-DTPA-D-Glu1-Minigastrin used for diagnosis of medullary thyroid carcinoma in comparison to 18F-FDG PET and CT scanning*. SNM, Los Angeles, 6/15/02-6/19/02.
34. T.M. Behr, M. Gotthardt, **M. L. Schipper**, S. Gratz, H. Höffken, M. Béhé: *Cholecystinin(CCK)-Bgastrin-receptor binding peptides for diagnosis and therapy of metastatic medullary thyroid cancer (MTC)*. SNM, Los Angeles, 6/15/02-6/19/02.
35. T.M. Behr, M. Gotthardt, **M. L. Schipper**, S. Gratz, H. Höffken, M. Béhé: *In-111-DTPA-D-Glu1-Minigastrin for receptor-targeted radiotherapy of neuroendocrine tumors: results of an ongoing dose-escalation-study*. SNM, Los Angeles, 6/15/02-6/19/02.
36. T.M. Behr, M. Gotthardt, **M. L. Schipper**, S. Gratz, G. Brittinger, B. Wörmann, W. Becker, M. Béhé: *High-dose myeloablative versus conventional low-dose radioimmunotherapy (RIT) of mantle cell lymphoma (MCL) with the chimeric anti-CD20 antibody C2B8*. SNM, Los Angeles, 6/15/02-6/19/02.
37. Barth, T.M. Behr, K. S. Kolbert, **M. L. Schipper**, M. Gotthardt, M. Béhé, G. Sgouros: *Patient-specific dosimetry for 111In-octreotide therapy*. SNM, Los Angeles, 6/15/02-6/19/02.
38. H. Hoeffken, A. Gerstner, A. Bayraktar, M. Gotthardt, **M. L. Schipper**, A. Schlieck, S. Gratz, W. H. Oertel, T. M. Behr: *Prospective evaluation of combined 123I-FP-CIT and 123I-IBZM- SPECT in the differential diagnosis of Parkinson's syndrome*. SNM, Los Angeles, 6/15/02-6/19/02.
39. M. Gotthardt, M. Béhé, **M. L. Schipper**, A. Barth, A. Schlieck, S. Gratz, H. Hoeffken, T. M. Behr: *111-DTPA-D-Glu1-Minigastrin compared to 18F-FDG-PET and CT scanning in the diagnosis of medullary thyroid carcinoma*. 15th international IRIST meeting, Rotterdam, Netherlands, 5/24/02-5/25/02.
40. **M. L. Schipper**, M. Gotthardt, M. Béhé, J. Dietrich, M. U. Wied, R. Arnold, T.M. Behr: *Therapeutic efficacy and toxicity of In-111-DTPA-D-Phe-Octreotide in patients with metastatic neuroendocrine tumors: preliminary results of a dose-escalation-study*. DGN, Freiburg, Germany, 4/10/02-4/13/02.
41. M. Gotthardt, **M. L. Schipper**, M. Béhé, H. Höffken, A. Schlieck, S. Gratz, T.M. Behr: *In-111-DTPA-D-Glu1-Minigastrin in der Rezeptor-gerichteten Radiotherapie von neuroendokrinen Tumoren: Initiale klinische Ergebnisse einer laufenden Dosisescalationsstudie*. DGN, Freiburg, Germany, 4/10/02-4/13/02.
42. M. Gotthardt, **M. L. Schipper**, M. Groß, H. Klaus, M. Béhé, R. Engenhardt-Cabilic, T.M. Behr: *Verwendung von In-111-DTPA-D-Glu1-Minigastrin für die Vitalitätsdiagnostik von Hirntumoren: Initiale klinische Ergebnisse*. DGN, Freiburg, Germany, 4/10/02-4/13/02.
43. M. Gotthardt, M. Béhé, **M. L. Schipper**, H. Höffken, J. Djomotschko, K. Goecke, T.M. Behr: *In-111-DTPA-D-Glu1-Minigastrin in der Diagnostik des medullären Schilddrüsenkarzinoms im Vergleich zu F-18-FDG-PET und CT*. DGN, Freiburg, Germany, 4/10/02-4/13/02.